Karyopharm Therapeutics Inc. (KPTI) NASDAQ

9.23

-0.59(-6.01%)

Updated at June 02 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Richard A. Paulson	President, Chief Executive Officer & Director	1.24M	1967
Michael J. Mano	Executive VP, Chief Legal Officer & Secretary	625,075	1977
Lori A. Macomber	Executive Vice President, Chief Financial Officer & Treasurer	712,680	1971
Sohanya Cheng	Executive Vice President, Chief Commercial Officer & Head of Business Development	779,035	1984
Stuart Poulton	Executive Vice President & Chief Development Officer	971,551	1973
Sharon Shacham	Co-Founder & Chairman of Scientific Advisory Board	1.4M	1970
Reshma Rangwala	Executive Vice President, Chief Medical Officer & Head of Research	1.82M	1978
Amama Sadiq	Senior Vice President of Global Medical & Scientific Affairs	0	N/A
Brendan Twohig Strong	Senior Vice President of Investor Relations	0	N/A
Brian Austad	Senior Vice President of Pharmaceutical Sciences	0	N/A
James Accumanno	Chief Compliance Officer	0	N/A
Lisa DiPaolo	Executive Vice President & Chief Human Resource Officer	0	N/A
Kristin Abate	Vice President, Chief Accounting Officer & Assistant Treasurer	0	N/A

Name

Title

Pay

Year Born

Richard A. Paulson

President, Chief Executive Officer & Director

1.24M

1967

Michael J. Mano

Executive VP, Chief Legal Officer & Secretary

625,075

1977

Lori A. Macomber

Executive Vice President, Chief Financial Officer & Treasurer

712,680

1971

Sohanya Cheng

Executive Vice President, Chief Commercial Officer & Head of Business Development

779,035

1984

Stuart Poulton

Executive Vice President & Chief Development Officer

971,551

1973

Sharon Shacham

Co-Founder & Chairman of Scientific Advisory Board

1.4M

1970

Reshma Rangwala

Executive Vice President, Chief Medical Officer & Head of Research

1.82M

1978

Amama Sadiq

Senior Vice President of Global Medical & Scientific Affairs

N/A

Brendan Twohig Strong

Senior Vice President of Investor Relations

N/A

Brian Austad

Senior Vice President of Pharmaceutical Sciences

N/A

James Accumanno

Chief Compliance Officer

N/A

Lisa DiPaolo

Executive Vice President & Chief Human Resource Officer

N/A

Kristin Abate

Vice President, Chief Accounting Officer & Assistant Treasurer

N/A

Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.